Apogee Therapeutics (APGE) CMO trades stock under 10b5-1 plan

Rhea-AI Filing Summary

Apogee Therapeutics’ Chief Medical Officer Carl Dambkowski exercised stock options for 4,125 shares of common stock at $22.8600 per share on August 5, 2026, and on the same date sold 5,500 shares at $134.1700 per share under a Rule 10b5-1 trading plan. After the option exercise, 110,665 option shares from this award remained outstanding; the option originally covered 175,345 shares vesting in 48 equal monthly installments through December 18, 2027.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Dambkowski Carl

Role Chief Medical Officer

Sold 5,500 shs ($738K)

Approx. gross sale proceeds $738K

Approx. exercise cost $94K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F2	4,125	$0.00	$0.00
Exercise	Common Stock	4,125	$22.86	$94K
Sale	Common Stock F1	5,500	$134.17	$738K

Holdings After Transaction: Stock Option (Right to Buy) — 110,665 shares (Direct); Common Stock — 168,498 shares (Direct)

Footnotes (2)

1. F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025.
2. F2. This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer.

Key Figures

Options exercised: 4,125 shares Exercise price: $22.8600 per share Shares sold: 5,500 shares +4 more

7 metrics

Options exercised 4,125 shares Stock options exercised into common stock on August 5, 2026 at $22.8600 per share

Exercise price $22.8600 per share Exercise price for 4,125 stock options converted into common stock

Shares sold 5,500 shares Common stock sold on August 5, 2026 at $134.1700 per share

Sale price $134.1700 per share Per-share price for the 5,500 common shares sold by the CMO

Remaining option shares 110,665 shares Option shares remaining outstanding from the reported award after the exercise

Option grant size 175,345 shares Total shares covered by the stock option that vests monthly through December 18, 2027

Vesting installments 48 monthly installments Vesting schedule for the 175,345-share option award through December 18, 2027

Key Terms

Rule 10b5-1 trading plan, Stock Option (Right to Buy), vest in forty-eight equal monthly installments

3 terms

Rule 10b5-1 trading plan financial

"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy) with an exercise price of 22.8600"

vest in forty-eight equal monthly installments financial

"which will vest in forty-eight equal monthly installments through December 18, 2027"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/07/2026 - 08:00 PM Accepted by SEC EDGAR 08/07/2026 - 08:00 PM Learn about SEC filing dates

FAQ

What insider transactions did Apogee Therapeutics (APGE) report for its CMO?

Apogee Therapeutics’ CMO, Carl Dambkowski, exercised options for 4,125 shares at $22.8600 and sold 5,500 shares at $134.1700 on August 5, 2026, combining an option exercise with an open-market share sale.

At what prices did the Apogee Therapeutics (APGE) insider trades occur?

Carl Dambkowski exercised stock options at an exercise price of $22.8600 per share and sold common shares at $134.1700 per share. Both transactions took place on August 5, 2026, as part of a reported insider trading sequence.

Was the Apogee Therapeutics (APGE) insider sale under a Rule 10b5-1 plan?

Yes. The sale of 5,500 shares of Apogee Therapeutics common stock by Carl Dambkowski was executed under a Rule 10b5-1 trading plan adopted on September 22, 2025, indicating the sale followed a pre-arranged trading schedule.

How many Apogee Therapeutics (APGE) option shares remain after the CMO’s exercise?

Following the reported option exercise, 110,665 option shares from the referenced award remained outstanding. The option originally represented the right to purchase 175,345 shares of Apogee Therapeutics common stock, subject to ongoing vesting requirements.

What is the vesting schedule for the Apogee Therapeutics (APGE) option grant?

The option grant referenced for Carl Dambkowski covers 175,345 shares and will vest in 48 equal monthly installments through December 18, 2027, conditioned on his continued service to Apogee Therapeutics as disclosed in the report’s footnote.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dambkowski Carl

(Last) (First) (Middle)

C/O APOGEE THERAPEUTICS, INC.

1 LETTERMAN DRIVE, BUILDING B

(Street)

SAN FRANCISCO CALIFORNIA 94129

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Apogee Therapeutics, Inc. [ APGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/05/2026		M		4,125	A	$22.86	173,998	D
Common Stock	08/05/2026		S(1)		5,500	D	$134.17	168,498	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$22.86	08/05/2026		M			4,125	(2)	12/18/2033	Common Stock	4,125	$0.00	110,665	D

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025.

2. This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer.

	/s/ Matthew Batters, as attorney-in-fact for Carl Dambkowski	08/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)